NXGL vs. CTSO, LUCD, NUVO, DXR, ICCM, DRIO, XAIR, ICAD, TTOO, and AMIX
Should you be buying NEXGEL stock or one of its competitors? The main competitors of NEXGEL include Cytosorbents (CTSO), Lucid Diagnostics (LUCD), Holdco Nuvo Group D.G (NUVO), Daxor (DXR), IceCure Medical (ICCM), DarioHealth (DRIO), Beyond Air (XAIR), iCAD (ICAD), T2 Biosystems (TTOO), and Autonomix Medical (AMIX). These companies are all part of the "surgical & medical instruments" industry.
NEXGEL (NASDAQ:NXGL) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, community ranking, earnings, valuation and media sentiment.
NEXGEL has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.
In the previous week, Cytosorbents had 1 more articles in the media than NEXGEL. MarketBeat recorded 1 mentions for Cytosorbents and 0 mentions for NEXGEL. NEXGEL's average media sentiment score of 0.00 equaled Cytosorbents'average media sentiment score.
NEXGEL has higher earnings, but lower revenue than Cytosorbents. NEXGEL is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.
NEXGEL has a net margin of -67.48% compared to Cytosorbents' net margin of -75.07%. NEXGEL's return on equity of -54.71% beat Cytosorbents' return on equity.
Cytosorbents has a consensus price target of $2.00, suggesting a potential upside of 127.17%. Given Cytosorbents' higher probable upside, analysts plainly believe Cytosorbents is more favorable than NEXGEL.
2.2% of NEXGEL shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 27.2% of NEXGEL shares are held by insiders. Comparatively, 6.6% of Cytosorbents shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Cytosorbents received 435 more outperform votes than NEXGEL when rated by MarketBeat users. Likewise, 78.99% of users gave Cytosorbents an outperform vote while only 50.00% of users gave NEXGEL an outperform vote.
Summary
NEXGEL and Cytosorbents tied by winning 8 of the 16 factors compared between the two stocks.
Get NEXGEL News Delivered to You Automatically
Sign up to receive the latest news and ratings for NXGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NXGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
